Article Information
vol. 60 no. suppl 66
Published By
Print ISSN
Online ISSN
History
- Published online January 24, 2023.
Copyright & Usage
Copyright ©the authors 2022
Author Information
- Daiana Stolz1⇑,
- Eleni Papakonstantinou2,
- Maria Pascarella3,
- Kathleen Jahn3,
- Aline Siebeneichler3,
- Andrei Darie3,
- Matthias Herrmann3,
- Werner Strobel3,
- Anna Salina3,
- Leticia Grize3 and
- Michael Tamm4
- 1Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland; Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland; Clinic of Respiratory Medicine, University of Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany, Freiburg, Germany
- 2Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland; Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland; Clinic of Respiratory Medicine, University of Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany, Basel, Switzerland
- 3Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland, Basel, Switzerland
- 4Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland; Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland, Basel, Switzerland
- Daiana Stolz, Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Switzerland; Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland; Clinic of Respiratory Medicine, University of Freiburg, Germany; Faculty of Medicine, University of Freiburg, Germany, Freiburg, Germany. E-mail: daiana.stolz{at}uniklinik-freiburg.de
Article usage
Altmetrics
Vol 60 Issue suppl 66
Table of Contents
RCT Abstract - Airway smooth muscle mass to predict response to ICS in COPD patients receiving triple therapy (HISTORIC study): a randomized, placebo-controlled, double-blind, investigator-initiated trial
